Keyphrases
Allergy
18%
Area Index
16%
Atopic Dermatitis
83%
Atopic Eczema
24%
Autoantibodies
9%
Chronic Inflammatory Skin Disease
12%
Chronic mucocutaneous Candidiasis
14%
Comorbidity
11%
Dermatological Diseases
9%
Dermatologist
10%
Diffuse Cutaneous Systemic Sclerosis
14%
Digital Ulcers
10%
Disease Progression
15%
Dupilumab
32%
EAACI
11%
Eczema
51%
Epidermis
10%
EUSTAR
14%
Fumaric Acid Esters
14%
Generalized Pustular Psoriasis
15%
Germany
18%
Guselkumab
16%
Immune Response
19%
Inflammation
16%
Inflammatory Skin Diseases
28%
Interleukin-17 (IL-17)
40%
Interleukin-22 (IL-22)
24%
Interleukin-23 (IL-23)
10%
Itch
13%
Keratinocytes
23%
Moderate-to-severe Atopic Dermatitis
39%
Moderate-to-severe Psoriasis
20%
Modified Rodnan Skin Score (mRSS)
9%
Molecular Diagnostics
14%
Optoacoustic Mesoscopy
19%
Pruritus
10%
Psoriasis
100%
Psoriasis Pathogenesis
15%
Raster Scanning
11%
Research Cohort
9%
Risk Factors
10%
Scleroderma
41%
Severity Index
16%
Skin Diseases
11%
Skin Fibrosis
11%
Systemic Sclerosis
46%
Systemic Treatment
10%
T Cells
25%
T Helper 17 (Th17)
19%
Upadacitinib
19%
Immunology and Microbiology
Allergen
6%
Atopic Dermatitis
60%
Atopy
8%
Autoantibodies
13%
B Cell
6%
Biological Product
7%
Candida
9%
Candida Albicans
5%
Chemokine
5%
Chronic Mucocutaneous Candidiasis
13%
Comorbidity
15%
Cytokine
47%
Dendritic Cell
7%
Dermatitis
43%
Dupilumab
12%
Eczema
61%
Gene Expression
9%
Hapten
6%
Immune Response
29%
Immunocompetent Cell
8%
Immunoglobulin E
7%
Immunotherapy
6%
Innate Immune System
12%
Interleukin 17
41%
Interleukin 22
8%
Interleukin 4
6%
Interleukin 6
6%
Keratinocyte
34%
Macrophage
6%
Mediator
6%
Microbiome
10%
Neutrophil
6%
Patch Test
6%
Prevalence
12%
Scleroderma
31%
Secretion (Process)
7%
Skin Allergy
12%
Supernatant
6%
Synovitis
8%
Systemic Inflammation
7%
Systemic Scleroderma
47%
T Cell
37%
Th17 Cell
7%
Th22 Cell
7%
Toll-Like Receptor
7%
Transcription Factors
5%
Transcriptome
6%
Transcriptomics
8%
Tumor Necrosis Factor
9%
Wound Healing
8%
Medicine and Dentistry
Apremilast
5%
Atopic Dermatitis
51%
Autoantibodies
5%
Biological Marker
20%
Biological Product
8%
Chronic Urticaria
5%
Clinical Trial
6%
COVID-19
5%
Cytokine
8%
Dermatitis
25%
Dermatological Disease
6%
Dermatology
31%
Disease Course
7%
Disease Duration
9%
Disease Exacerbation
12%
Disease Severity
6%
Diseases
40%
Dupilumab
9%
Eczema
31%
Finger Ulcer
7%
Fumaric Acid
8%
Generalized Pustular Psoriasis
11%
Guselkumab
11%
Hand Eczema
9%
Infection
10%
Inflammatory Disorder
7%
Interleukin 17
12%
Keratinocyte
7%
Lebrikizumab
5%
Lung
5%
Molecular Diagnostics
9%
Mucocutaneous Candidiasis
5%
Personalized Medicine
9%
Prevalence
5%
Prospective Study
5%
Pruritus
10%
Psoriasis
54%
Psoriasis Vulgaris
13%
Quality of Life
5%
Scleroderma
25%
Severe Acute Respiratory Syndrome Coronavirus 2
6%
Skin Disease
5%
Skin Fibrosis
8%
Synovitis
7%
Systemic Scleroderma
44%
Systemic Therapy
16%
T Cell
10%
Targeted Therapy
5%
Treatment Response
6%
Upadacitinib
5%
